Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Resources, news and special offers to support you and your professional development during this difficult time.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Download your copy of the new events calendar and see all the online workshops, conferences, RAC exams and European online workshops RAPS has planned for 2021 at a glance.
Registration is now open for RAPS Euro Convergence 2021! Attend to join peers from EU and around the world to gain insights and exchange ideas on the regions most pressing issues.
An invaluable resource for any professional engaged in designing, composing, compiling, or commenting on regulatory documentation
From self-assessments to help you identify your strengths and areas to focus on to reference books and online courses that will help you fill in the gaps in your regulatory knowledge, RAPS has the resources to help you prepare for the RAC exam.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
Posted 09 July 2013 | By Alexander Gaffney, RAC,
On a normative level, choice is good, especially in the US where the notion of economic choice is quite literally the foundation of a capitalist economy. If you're in the market for a new car, for example, it's comforting to know that you're no longer restricted to a black Ford Model "T," as were early American consumers. And if you're looking to eat lunch, the variety of options may well prove dizzying.
But the one place where choice isn't quite as welcome is at the US Food and Drug Administration (FDA), which recently sent a Warning Letter to a medical device manufacturer after the company allegedly offered a variety of options meant to customize a medical device without first seeking or receiving agency approval.
The letter, released 9 July 2013, is to Biomedix, a Bloomington, Indiana-based company that manufacturers the Selec-3 Intravenous (IV) Administration Set. The product was originally cleared through FDA's 510(k) premarket notification pathway in 1993, having been found to be substantially equivalent to other IV administration sets.
But during a February and March 2013 inspection of the company's facility, FDA inspectors found a number of violations that caused the device to become adulterated and misbranded.
The problem, FDA explained in its Warning Letter, is that Biomedix "has modified the Selec-3 Intravenous (IV) Administration Sets originally cleared under K901949, K925645 and K961928 by providing customers with an ordering system to alter the device through various options and configurations." For example, customers could order different lengths of IV tubing, an optional vented spike, optional luer activated y-sites, and optional needleless luer y-sites, FDA said.
And while customization is often in the interests of consumers, and particularly those with unique needs, such customization is not without risks for medical devices. FDA explained that, "Depending on the configuration of the new components and customization, the functionality of the device can change beyond what was 510(k) cleared."
"These combinations of features can alter the performance of the device and require a new 510(k) submission," it added.
As a result, the company would have been required to have an approved investigational device exemption (IDE) under section 510(g) of the Federal Food, Drug and Cosmetic Act (FD&C Act), or an approved application under section 510(k) or 515(a), also known as premarket approval (PMA). Accordingly, the devices were found to be misbranded and adulterated, and FDA said the company would need to immediately rectify the situation.
Warning Letter to Biomedix
Regulatory Focus newsletters
All the biggest regulatory news and happenings.